Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
PR Newswire•16/11/2026•08:00 ET
0
Key Highlights
- ➤Clinical benefit rate 81.5% after nearly 40 months in Grade 2 IDH1-mutant glioma
- ➤Confirmed objective response rate 51.9%, including 14.8% partial responses
- ➤Median target lesion reduction reached 27.2%; response duration not yet reached
- ➤Safusidenib exposure median 46.7 months, with no new safety signals
- ➤FDA granted Fast Track designation for safusidenib in August 2026
Expert Statements
Yoshiki Arakawa, M.D., Ph.D., Kyoto University Graduate School of Medicine and lead author
“The mature data presented at SNO—highlighted by a clinical benefit rate above 80%, sustained tumor shrinkage, and a low discontinuation rate over nearly four years of median exposure—further support safusidenib as a promising therapy that could provide meaningful, long-term disease control while deferring more toxic interventions.”
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio
“These compelling long-term data reinforce our confidence in safusidenib's differentiated profile and potential to deliver sustained disease control”
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting PR Newswire
With nearly 40 months of follow-up, additional updated data from J201 study show the confirmed clinical benefit rate was 81.5% in patients with Grade 2 IDH1-mutant glioma
Get started
Create a free account to read the full story.
